Glen Eagle Advisors, LLC Next Cure, Inc. Transaction History

Glen Eagle Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Aug 13, 2024	SELL	$8.15 - $21.17 $1,263 - $3,281	-155 Closed	0 $0
Q2 2020 Aug 13, 2024	BUY	$21.19 - $40.2 $2,224 - $4,221	105 Added 210.0%	155 $3.32 Million
Q1 2020 Aug 13, 2024	BUY	$32.32 - $58.37 $969 - $1,751	30 Added 150.0%	50 $1.85 Million
Q4 2019 Aug 13, 2024	BUY	$25.0 - $92.22 $500 - $1,844	20 New	20 $1.13 Million

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $31.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.